New Zealand markets open in 2 hours 4 minutes

Hangzhou Alltest Biotech Co., Ltd. (688606.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
67.52+0.04 (+0.06%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 5.35B
Enterprise value 2.66B
Trailing P/E 28.96
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.45
Price/book (mrq)1.39
Enterprise value/revenue 3.71
Enterprise value/EBITDA 13.33

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 33.74%
S&P500 52-week change 325.38%
52-week high 381.10
52-week low 346.02
50-day moving average 363.82
200-day moving average 362.57

Share statistics

Avg vol (3-month) 3508.5k
Avg vol (10-day) 3709.06k
Shares outstanding 579.28M
Implied shares outstanding 680.55M
Float 88.61M
% held by insiders 166.72%
% held by institutions 13.77%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 410
Forward annual dividend yield 414.82%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4429.18%
Dividend date 3N/A
Ex-dividend date 409 Jun 2023
Last split factor 21.48:1
Last split date 309 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 25.73%
Operating margin (ttm)25.76%

Management effectiveness

Return on assets (ttm)1.68%
Return on equity (ttm)4.58%

Income statement

Revenue (ttm)718.48M
Revenue per share (ttm)9.06
Quarterly revenue growth (yoy)-15.30%
Gross profit (ttm)N/A
EBITDA 137.51M
Net income avi to common (ttm)184.83M
Diluted EPS (ttm)2.33
Quarterly earnings growth (yoy)10.50%

Balance sheet

Total cash (mrq)2.71B
Total cash per share (mrq)33.87
Total debt (mrq)21.63M
Total debt/equity (mrq)0.56%
Current ratio (mrq)10.72
Book value per share (mrq)47.99

Cash flow statement

Operating cash flow (ttm)241.52M
Levered free cash flow (ttm)-352.83M